294648-01-4

Basic information

• Product Name: 9H-Purin-6-amine, 2-chloro-9-(1-methylethyl)-N-[[4-(2-pyridinyl)phenyl]methyl]-
• CAS NO: 294648-01-4
• Molecular Formula: C20H19ClN6
• Molecular Weight: 378.864
• Mol File: 294648-01-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 9H-Purin-6-amine, 2-chloro-9-(1-methylethyl)-N-[[4-(2-pyridinyl)phenyl]methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 9H-Purin-6-amine, 2-chloro-9-(1-methylethyl)-N-[[4-(2-pyridinyl)phenyl]methyl]-(294648-01-4)
• EPA Substance Registry System: 9H-Purin-6-amine, 2-chloro-9-(1-methylethyl)-N-[[4-(2-pyridinyl)phenyl]methyl]-(294648-01-4)

Safety Data

• Hazardous Substances Data: 294648-01-4(Hazardous Substances Data)

Upstream product

• 5451-40-1 2,6-dichloro-7H-purine 
• 294647-99-7 2-chloro-6-[4-(2-pyridyl)phenylmethylamino]-purine 
• 75-26-3 isopropyl bromide 
• 294647-99-7 2-chloro-6-[4-(2-pyridyl)phenylmethylamino]purine 
• 294647-97-5 1-[4-(pyridin-2-yl)phenyl]methanamine 
• 203436-45-7 2,6-dichloro-9-isopropyl-9H-purine 

Downstream Products

• 294646-77-8 (R)-CR8 
• 1056016-22-8 (R)-2-(1-hydroxy-3-methylbut-2-ylamino)-6-[4-(2-pyridyl)phenylmethylamino]-9-iso-propylpurine 
• 1056016-24-0 2-(1-hydroxy-2-methylprop-2-ylamino)-6-[4-(2-pyridyl)phenylmethylamino]-9-iso-propylpurine 
• 1243148-40-4 (S)-3-[9-isopropyl-6-(4-pyridin-2-yl-benzylamino)-9H-purin-2-ylamino]-propane-1,2-diol 
• 1130281-21-8 2-(1,3-Dihydroxyprop-2-ylamino)-6-[4-(2-pyridyl)phenylmethylamino]-9-isopropylpurine 

Relevant articles and documents

Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors

A new series of 2,6,9-trisubstituted purines, structurally related to the cyclin-dependent kinase (CDK) inhibitor Roscovitine, has been synthesized. These compounds mainly differ by the substituent on the C-2 position which encompasses a diol group. These

METHOD OF TREATMENT OF POLYCYSTIC DISEASES AND CHRONIC LYMPHOCYTIC LEUKEMIA

The present invention concerns a method of treatment of polycystic diseases or of reducing and/or avoiding cyst formation in a patient with cystic disease, which comprises at least one step consisting in administering to said patient an effective amount of a 2,6,9-trisubstituted purine compound of formula (VII): wherein A represents alternatively a (A.1) or (A.2) group.

Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1

Cyclin-dependent kinases (CDKs) and casein kinases 1 (CK1) are involved in the two key molecular features of Alzheimer's disease, production of amyloid-β peptides (extracellular plaques) and hyper-phosphorylation of Tau (intracellular neurofibrillary tangles). A series of 2,6,9-trisubstituted purines, structurally related to the CDK inhibitor roscovitine, have been synthesized. They mainly differ by the substituent on the C-6 position. These compounds were screened for kinase inhibitory activities and antiproliferative effects. Several biaryl derivatives displayed potent inhibition of both CDKs and CK1. In particular, derivative 13a was a potent inhibitor of CDK1/cyclin B (IC50: 220 nM), CDK5/p25 (IC50: 80 nM), and CK1 (IC 50: 14 nM). Modeling of these molecules into the ATP-binding pocket of CK1δ provided a rationale for the increased selectivity toward this kinase. 13a was able to prevent the CK1-dependent production of amyloid-β in a cell model. CDK/CK1 dual-specificity inhibitors may have important applications in Alzheimer's disease and cancers.